Goldman Sachs initiates Option Care Health stock coverage at neutral

Goldman Sachs initiated Option Care Health at Neutral with a $22 price target versus a $20.51 share price, citing long-term specialty infusion growth but near-term earnings uncertainty from chronic portfolio disruption. The stock is down 33% over the past six months, and 9 analysts have cut earnings estimates for the next period. Q1 2026 results were mixed, with adjusted EPS of $0.40 beating the $0.38 consensus while revenue missed at $1.35 billion versus $1.4 billion expected.

Analysis

The signal here is less about one quarter’s miss and more about a regime change in the earnings mix. OPCH is exposed to a classic “good business, bad cadence” setup: structural demand remains intact, but therapy-specific mix shifts can compress near-term revenue visibility faster than the market model can adjust, which tends to produce repeated estimate cuts before the fundamentals truly deteriorate. That usually creates a slower, grind-down de-rating rather than a single sharp reset, especially when sell-side coverage is still trying to triangulate normalized margins.

The second-order effect is competitive, not operational: if OPCH’s chronic portfolio stays choppy, smaller regional infusion players will struggle to absorb share because payor access and breadth matter more in a disrupted formulary environment. That can actually strengthen OPCH’s long-run moat, but only after a period of working-capital and utilization pressure; the interim losers are the vendors and service providers tied to higher-acuity chronic therapies, where ordering patterns can become lumpy and purchasing decisions get deferred. The market is likely underestimating how long it takes for a patient-census reset to flow through to cleaner comps, which can be multiple quarters, not weeks.

The contrarian angle is that consensus may be over-penalizing a business with decent franchise quality for what is largely timing noise plus a category-level mix issue. If the next 1-2 quarters show stabilization in chronic volume or better conversion on the specialty side, the stock can re-rate quickly because expectations are already compressed and the balance sheet/health profile limits downside from a solvency perspective. The key is that a “neutral” rating can still be bullish tactically if the market has already priced in a prolonged deterioration that does not materialize.

Key Decisions for Investors

• Stay tactically underweight OPCH for the next 1-2 quarters until revenue stabilization is visible; the risk/reward favors waiting for a cleaner operating inflection rather than catching a falling estimate cycle.
• If long healthcare services exposure is needed, pair long HUM or CNC against short OPCH over 3-6 months to express preference for businesses with less therapy-specific revenue volatility and better reimbursement visibility.
• Sell downside-protected puts on OPCH only after the next earnings release if the stock remains >20% below prior highs; use the premium to monetize the elevated uncertainty while defining entry risk.
• For event-driven traders, look to buy OPCH only on a post-earnings capitulation day with volume >2x normal and no new guidance cut; target a 15-20% mean-reversion bounce if the market decides the miss was purely timing-related.
• Avoid chasing a short here unless the next update confirms another revenue shortfall; the stock’s already compressed expectations mean the cleanest short thesis requires evidence of a multi-quarter demand reset.